Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NYSE:QGEN NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.72+2.2%$4.41$1.72▼$8.21$619.48M2.183.24 million shs2.35 million shsEDITEditas Medicine$2.60+5.7%$2.79$1.47▼$4.54$240.85M2.141.19 million shs1.37 million shsQGENQiagen$35.07+2.4%$38.46$32.53▼$57.81$7.06B0.642.67 million shs1.65 million shsSRPTSarepta Therapeutics$17.12+2.9%$20.02$10.41▼$44.14$1.76B0.263.14 million shs2.29 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics+4.00%-6.19%-24.48%-32.72%+70.89%EDITEditas Medicine-2.77%-16.04%-29.51%+43.02%+65.10%QGENQiagen+1.46%+1.78%-16.90%-30.13%-23.89%SRPTSarepta Therapeutics-2.18%-13.02%-22.78%-9.47%-56.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.72+2.2%$4.41$1.72▼$8.21$619.48M2.183.24 million shs2.35 million shsEDITEditas Medicine$2.60+5.7%$2.79$1.47▼$4.54$240.85M2.141.19 million shs1.37 million shsQGENQiagen$35.07+2.4%$38.46$32.53▼$57.81$7.06B0.642.67 million shs1.65 million shsSRPTSarepta Therapeutics$17.12+2.9%$20.02$10.41▼$44.14$1.76B0.263.14 million shs2.29 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics+4.00%-6.19%-24.48%-32.72%+70.89%EDITEditas Medicine-2.77%-16.04%-29.51%+43.02%+65.10%QGENQiagen+1.46%+1.78%-16.90%-30.13%-23.89%SRPTSarepta Therapeutics-2.18%-13.02%-22.78%-9.47%-56.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.91Moderate Buy$12.10225.27% UpsideEDITEditas Medicine 2.57Moderate Buy$5.40107.69% UpsideQGENQiagen 2.50Moderate Buy$44.9828.27% UpsideSRPTSarepta Therapeutics 2.11Hold$27.7161.85% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/18/2026QGENQiagen Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$50.00 ➝ $36.005/18/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/12/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.005/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$46.00 ➝ $40.005/5/2026EDITEditas Medicine Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.004/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$76.20M8.31N/AN/A$1.88 per share1.98EDITEditas Medicine$40.52M6.28N/AN/A$0.05 per share52.00QGENQiagen$2.09B3.46$3.49 per share10.06$16.17 per share2.17SRPTSarepta Therapeutics$2.20B0.82N/AN/A$14.26 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)EDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%N/AQGENQiagen$424.88M$1.9118.3113.183.4119.16%14.40%8.40%8/4/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A7.480.19-2.94%7.56%2.94%8/5/2026 (Estimated)Latest SRPT, CTMX, EDIT, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million3/16/2026Q4 2025CTMXCytomX Therapeutics-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 million3/9/2026Q4 2025EDITEditas Medicine-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 million2/25/2026Q4 2025SRPTSarepta Therapeutics-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AQGENQiagen$0.260.74%N/A13.61%N/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ALatest SRPT, CTMX, EDIT, and QGEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A10.3810.38EDITEditas MedicineN/A3.223.22QGENQiagen0.493.212.57SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%QGENQiagen70.00%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%EDITEditas Medicine3.10%QGENQiagen9.00%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170170.19 million158.96 millionOptionableEDITEditas Medicine23097.91 million94.87 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableSRPT, CTMX, EDIT, and QGEN HeadlinesRecent News About These CompaniesWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20 at 1:15 PM | finance.yahoo.comWhy Elevidys Matters For Sarepta Therapeutics Inc (SRPT) StockMay 20 at 9:31 AM | insidermonkey.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19 at 12:43 PM | proactiveinvestors.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)May 17 at 5:48 PM | theglobeandmail.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by BrokeragesMay 16, 2026 | americanbankingnews.comSarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target UnchangedMay 15, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Sarepta Therapeutics (SRPT) and Surgery Partners (SGRY)May 14, 2026 | theglobeandmail.comSarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Built On Soft FoundationsMay 14, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | finance.yahoo.comSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | businesswire.comSarepta Therapeutics (SRPT) Gets a Buy from OppenheimerMay 12, 2026 | theglobeandmail.comWells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)May 11, 2026 | theglobeandmail.comA Look At Sarepta Therapeutics (SRPT) Valuation After Q1 Profitability Return And Pipeline ProgressMay 9, 2026 | finance.yahoo.comVanguard Group Inc. Grows Stock Holdings in Sarepta Therapeutics, Inc. $SRPTMay 9, 2026 | marketbeat.comSarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush SaysMay 8, 2026 | finance.yahoo.comSarepta (SRPT) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comSRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growthMay 8, 2026 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 11.8% - Should You Sell?May 7, 2026 | marketbeat.comSarepta Therapeutics, Inc. Q1 2026 Earnings Call SummaryMay 7, 2026 | app.moby.coASarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.May 7, 2026 | finance.yahoo.comSarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?May 7, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026NerdWallet’s Growth Story Looks Strong—But Can It Last?By Peter Frank | April 30, 2026Viking Sails to All-Time Highs—Fundamentals Signal More to ComeBy Chris Markoch | May 15, 2026Capital One’s Big Bet Faces Rising Credit RiskBy Peter Frank | May 6, 2026SRPT, CTMX, EDIT, and QGEN Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$3.72 +0.08 (+2.20%) Closing price 04:00 PM EasternExtended Trading$3.74 +0.02 (+0.51%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$2.60 +0.14 (+5.69%) Closing price 04:00 PM EasternExtended Trading$2.59 -0.01 (-0.35%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Qiagen NYSE:QGEN$35.07 +0.83 (+2.41%) Closing price 03:59 PM EasternExtended Trading$35.09 +0.02 (+0.07%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Sarepta Therapeutics NASDAQ:SRPT$17.12 +0.48 (+2.88%) Closing price 04:00 PM EasternExtended Trading$17.07 -0.05 (-0.29%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
